BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

700 related articles for article (PubMed ID: 23525575)

  • 1. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
    Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
    Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
    Han SY; Zhao MB; Zhuang GB; Li PP
    Lung Cancer; 2012 Jan; 75(1):30-7. PubMed ID: 21757251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
    Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
    Gadgeel SM; Wozniak A
    Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
    Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
    Morgillo F; Sasso FC; Della Corte CM; Vitagliano D; D'Aiuto E; Troiani T; Martinelli E; De Vita F; Orditura M; De Palma R; Ciardiello F
    Clin Cancer Res; 2013 Jul; 19(13):3508-19. PubMed ID: 23695170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
    Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K
    Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
    Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines.
    La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Ardizzoni A; Tiseo M; Capelletti M; Goldoni M; Tagliaferri S; Mutti A; Fumarola C; Bonelli M; Generali D; Petronini PG
    Biochem Pharmacol; 2009 Sep; 78(5):460-8. PubMed ID: 19427302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.
    Choi YJ; Rho JK; Jeon BS; Choi SJ; Park SC; Lee SS; Kim HR; Kim CH; Lee JC
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):381-8. PubMed ID: 19921194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
    Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined treatment with Epimedium koreanum Nakai extract and gefitinib overcomes drug resistance caused by T790M mutation in non-small cell lung cancer cells.
    Song J; Zhong R; Huang H; Zhang Z; Ding D; Yan H; Sun E; Jia X
    Nutr Cancer; 2014; 66(4):682-9. PubMed ID: 24738693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
    Tracy S; Mukohara T; Hansen M; Meyerson M; Johnson BE; Jänne PA
    Cancer Res; 2004 Oct; 64(20):7241-4. PubMed ID: 15492241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
    Li XY; Wu JZ; Cao HX; Ma R; Wu JQ; Zhong YJ; Feng JF
    Oncol Rep; 2013 May; 29(5):1975-82. PubMed ID: 23440266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
    Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
    Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.